193 related articles for article (PubMed ID: 28184014)
1. Autophagy Inhibition Enhances Sunitinib Efficacy in Clear Cell Ovarian Carcinoma.
DeVorkin L; Hattersley M; Kim P; Ries J; Spowart J; Anglesio MS; Levi SM; Huntsman DG; Amaravadi RK; Winkler JD; Tinker AV; Lum JJ
Mol Cancer Res; 2017 Mar; 15(3):250-258. PubMed ID: 28184014
[TBL] [Abstract][Full Text] [Related]
2. 4-Acetylantroquinonol B suppresses autophagic flux and improves cisplatin sensitivity in highly aggressive epithelial cancer through the PI3K/Akt/mTOR/p70S6K signaling pathway.
Liu M; Bamodu OA; Huang WC; Zucha MA; Lin YK; Wu ATH; Huang CC; Lee WH; Yuan CC; Hsiao M; Deng L; Tzeng YM; Yeh CT
Toxicol Appl Pharmacol; 2017 Jun; 325():48-60. PubMed ID: 28408137
[TBL] [Abstract][Full Text] [Related]
3. RhoB mediates antitumor synergy of combined ixabepilone and sunitinib in human ovarian serous cancer.
Vishnu P; Colon-Otero G; Kennedy GT; Marlow LA; Kennedy WP; Wu KJ; Santoso JT; Copland JA
Gynecol Oncol; 2012 Mar; 124(3):589-97. PubMed ID: 22115851
[TBL] [Abstract][Full Text] [Related]
4. LY2109761 enhances cisplatin antitumor activity in ovarian cancer cells.
Gao Y; Shan N; Zhao C; Wang Y; Xu F; Li J; Yu X; Gao L; Yi Z
Int J Clin Exp Pathol; 2015; 8(5):4923-32. PubMed ID: 26191185
[TBL] [Abstract][Full Text] [Related]
5. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D
Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272
[TBL] [Abstract][Full Text] [Related]
6. A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254).
Chan JK; Brady W; Monk BJ; Brown J; Shahin MS; Rose PG; Kim JH; Secord AA; Walker JL; Gershenson DM
Gynecol Oncol; 2018 Aug; 150(2):247-252. PubMed ID: 29921512
[TBL] [Abstract][Full Text] [Related]
7. Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma.
Hui EP; Lui VW; Wong CS; Ma BB; Lau CP; Cheung CS; Ho K; Cheng SH; Ng MH; Chan AT
Invest New Drugs; 2011 Dec; 29(6):1123-31. PubMed ID: 20467883
[TBL] [Abstract][Full Text] [Related]
8. Sphingosine kinase 1 as a potential therapeutic target in epithelial ovarian cancer.
Lee JW; Ryu JY; Yoon G; Jeon HK; Cho YJ; Choi JJ; Song SY; Do IG; Lee YY; Kim TJ; Choi CH; Kim BG; Bae DS
Int J Cancer; 2015 Jul; 137(1):221-9. PubMed ID: 25429856
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy.
Joshi AD; Loilome W; Siu IM; Tyler B; Gallia GL; Riggins GJ
PLoS One; 2012; 7(10):e44372. PubMed ID: 23056179
[TBL] [Abstract][Full Text] [Related]
10. Autophagy Inhibition Improves Sunitinib Efficacy in Pancreatic Neuroendocrine Tumors via a Lysosome-dependent Mechanism.
Wiedmer T; Blank A; Pantasis S; Normand L; Bill R; Krebs P; Tschan MP; Marinoni I; Perren A
Mol Cancer Ther; 2017 Nov; 16(11):2502-2515. PubMed ID: 28729403
[TBL] [Abstract][Full Text] [Related]
11. Dihydroberberine exhibits synergistic effects with sunitinib on NSCLC NCI-H460 cells by repressing MAP kinase pathways and inflammatory mediators.
Dai B; Ma Y; Wang W; Zhan Y; Zhang D; Liu R; Zhang Y
J Cell Mol Med; 2017 Oct; 21(10):2573-2585. PubMed ID: 28444871
[TBL] [Abstract][Full Text] [Related]
12. Identification of novel therapeutic targets in microdissected clear cell ovarian cancers.
Stany MP; Vathipadiekal V; Ozbun L; Stone RL; Mok SC; Xue H; Kagami T; Wang Y; McAlpine JN; Bowtell D; Gout PW; Miller DM; Gilks CB; Huntsman DG; Ellard SL; Wang YZ; Vivas-Mejia P; Lopez-Berestein G; Sood AK; Birrer MJ
PLoS One; 2011; 6(7):e21121. PubMed ID: 21754983
[TBL] [Abstract][Full Text] [Related]
13. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy.
Ebos JM; Lee CR; Christensen JG; Mutsaers AJ; Kerbel RS
Proc Natl Acad Sci U S A; 2007 Oct; 104(43):17069-74. PubMed ID: 17942672
[TBL] [Abstract][Full Text] [Related]
14. IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer.
Anglesio MS; George J; Kulbe H; Friedlander M; Rischin D; Lemech C; Power J; Coward J; Cowin PA; House CM; Chakravarty P; Gorringe KL; Campbell IG; ; Okamoto A; Birrer MJ; Huntsman DG; de Fazio A; Kalloger SE; Balkwill F; Gilks CB; Bowtell DD
Clin Cancer Res; 2011 Apr; 17(8):2538-48. PubMed ID: 21343371
[TBL] [Abstract][Full Text] [Related]
15. Potential benefit of Sunitinib in recurrent and refractory ovarian clear cell adenocarcinoma.
Rauh-Hain JA; Penson RT
Int J Gynecol Cancer; 2008; 18(5):934-6. PubMed ID: 18081793
[TBL] [Abstract][Full Text] [Related]
16. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.
Castillo-Avila W; Piulats JM; Garcia Del Muro X; Vidal A; Condom E; Casanovas O; Mora J; Germà JR; Capellà G; Villanueva A; Viñals F
Clin Cancer Res; 2009 May; 15(10):3384-95. PubMed ID: 19417025
[TBL] [Abstract][Full Text] [Related]
17. Antitumour activity of sunitinib in combination with gemcitabine in experimental pancreatic cancer.
Awasthi N; Schwarz MA; Schwarz RE
HPB (Oxford); 2011 Sep; 13(9):597-604. PubMed ID: 21843259
[TBL] [Abstract][Full Text] [Related]
18. Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma.
Chan KK; Wong OG; Wong ES; Chan KK; Ip PP; Tse KY; Cheung AN
Int J Cancer; 2018 Sep; 143(6):1456-1469. PubMed ID: 29663364
[TBL] [Abstract][Full Text] [Related]
19. Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma.
Stringer-Reasor EM; Baker GM; Skor MN; Kocherginsky M; Lengyel E; Fleming GF; Conzen SD
Gynecol Oncol; 2015 Sep; 138(3):656-62. PubMed ID: 26115975
[TBL] [Abstract][Full Text] [Related]
20. Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models.
Ciamporcero E; Miles KM; Adelaiye R; Ramakrishnan S; Shen L; Ku S; Pizzimenti S; Sennino B; Barrera G; Pili R
Mol Cancer Ther; 2015 Jan; 14(1):101-10. PubMed ID: 25381264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
